Overview

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Status:
Completed
Trial end date:
2018-05-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
AbbVie (prior sponsor, Abbott)
Treatments:
Adalimumab